Mutations of the TP53 gene and dysregulation of the TP53 pathway are important in the pathogenesis of many human cancers including lymphomas. Tumor suppression by p53 occurs via both transcription-dependent activities in the nucleus by which p53 regulates transcription of genes involved in cell cycle, DNA repair, apoptosis, signaling, transcription, and metabolism; and transcription-independent activities that induces apoptosis and autophagy in the cytoplasm. In lymphoid malignancies, the frequency of TP53 deletions and mutations is lower than in other types of cancer. Nonetheless, the status of TP53 is an independent prognostic factor in most lymphoma types. Dysfunction of TP53 with wild-type coding sequence can result from deregulated gene expression, stability and activity of p53.
The TP53/P53 gene (tumor protein p53), initially identified as an oncogene in 1979, has been recognized as a tumor suppressor gene since 1989. 1 Tumor suppressor p53 protein (cellular tumor antigen p53), is "the guardian of the genome," preserves genome stability under cellular stress, and is involved in various processes of development, differentiation, aging, and disease. 
. 3 It is believed that phosphorylation, acetylation and methylation in stressed cells release p53 from MDM2 inhibition and activate p53, whereas sumoylation and neddylation increase p53 stability by inhibiting ubiquitination and repress p53 function. 3, 4 The tumor suppressor function of p53 is reflected in its regulation of cell cycle arrest, DNA repair, apoptosis, senescence, and autophagy, through both transcription-dependent and -independent activities ( Figure 2 ).
Transcription-dependent activities (TA) of p53 are required for p53-dependent tumor suppression, as demonstrated in mouse models that succumb to thymic lymphomas due to expression of mutant p53 QS (Leu25Trp26 to Gln25Ser26), which abolishes p53 TA but retains its transcription-independent function of apoptosis intact. 5 TA of p53 in lymphocytes been correlated with inferior overall survival (OS) in patients with diffuse large B-cell lymphoma (DLBCL) 23 and significantly shorter treatment-free survival in CLL patients. 21 In human lymphoblastoid cell lines, 24 p53 induces let-7 miRNA family members, miRNAs (miR-142-3p, miR-142-5p) that are brought close to the 5' region of MYC due to a translocation, 25 ,26 five of seven miRNAs of the miR-17-92 cluster, and other potential oncomirs (miR-155, miR-145, miR-143, and miR-21), although p53 represses the miR-17-92
cluster in colorectal carcinomas. 27 In myeloma cells, p53-inducible miRs-192, -194 and -215 target MDM2 and therefore activate p53. 28 The aberrant expression and clinical importance of these miRNAs are summarized in Table 1 .
18,19,21,23,28-35
A3. Effect of p53 activities in lymphocytes
p53 simultaneously promotes cell cycle arrest, DNA repair, and apoptosis, prompting the question as to whether a cell dies or survives after repair. The choice between cell cycle arrest and apoptosis depends on cell type, cell cycle stage, extent of DNA damage, p53 level and ratio to p53 isoforms, external survival factors, and internal cellular setting. 4, 36, 37 Lymphocytes are prone to apoptosis under stress compared to other cell types that are prone to permanent cell cycle arrest, transformation, or mitotic catastrophe leading to p53-independent apoptosis or necrotic death. 37 Lethal hematopoietic syndrome resulting from an acute p53 response is characterized by massive apoptosis.
37
Drugs can modulate the balance of p53 functions. For example, RO-3306, a CDK1
inhibitor, blocks cell cycle arrest by inhibiting p53-mediated activation of p21 while enhances apoptosis by reducing levels of anti-apoptotic Bcl-2, survivin and MDM2, and thereby caused enhanced apoptosis in acute myeloid leukemia (AML) cell lines with WTp53. 38 On the other hand, when the downstream apoptotic pathway is blocked, or p53 is an apoptosis-deficient mutant, p53 in lymphocytes can enhance cell cycle arrest and senescence, characterized by irreversible growth arrest, and delay lymphomagenesis, as has been shown in several murine lymphoma models.
37,39-41
Apoptosis also appears to be affected by autophagy, although the role of autophagy in cell death or cancer remains debatable. Autophagy correlates with drug resistance and tumor progression in several lymphoid malignancies. In a Myc-induced model of lymphoma, inhibition of autophagy by either chloroquine, an inhibitor of late autophagy, or short hairpin RNA for ATG5, a key autophagy gene, enhanced p53-dependent and -independent apoptosis, suggesting that autophagy is a survival pathway in lymphoma progression. 42 Chloroquine
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44

B. Loss of p53-function and lymphomagenesis
In p53-deficient mouse models, either absence 45, 46 or loss-of-function, 47 malignant lymphoma is the predominant tumor type. Loss of phosphorylation of Ser15 and Ser20 in human p53 was associated with lymphomagenesis of loss-of-apoptosis in p53-mut mice p53 18A , p53
23A
, and p53 S18/23A (Ser18/23 to Ala). In contrast with p53 -/-mice, which predominantly develop thymic T-cell lymphomas within 6 months, 45 ,46 most p53 S23A mice develop late-onset B-cell lymphomas in lymph node and spleen; 48 some p53 S18A mice develop a spectrum of malignancies with late onset, including B-lineage lymphomas and occasionally leukemia. 49 Interestingly, no increase in spontaneous tumorigenesis was observed in double-mutant p53 S18/23A mice but accelerated aging did occur.
3,49
Disruption of p53-dependent apoptosis is essential for the development and progression of lymphoproliferative diseases. 37,50,51 Overexpression of anti-apoptotic Bcl-2, Bcl-X(L), XIAP (X-linked inhibitor of apoptosis protein) and survivin, or deletion/silencing of pro-apoptotic genes, inactivates the intrinsic apoptotic pathway and is implicated in lymphomagenesis. For example, Bcl-2 overexpression resulting from the t(14;18)(q32;q21) in follicular lymphomas (FL), and deletion, mutation, or silencing of BIM and NOXA in mantle cell lymphoma (MCL), Burkitt lymphoma (BL), and DLBCL, 52 appear to be necessary events in lymphoma development.
C. Mechanisms of TP53 dysfunction in lymphoid malignancies
TP53 dysfunction in lymphoid malignancies can arise at the DNA, mRNA or protein level in cis or in trans, as summarized in Table 2 and Figure 5 .
C1. Mutations and polymorphisms of TP53 CDS
p53 mutation patterns
Mutations in the TP53 CDS have been extensively studied. Single allele mutations are frequently followed by loss of heterozygosity, which further promotes tumor development. 55 The transcription-independent p53 function is also impaired in many mutants. For example, upon doxorubicin treatment p53 mutants in human lymphoma cells can still translocate to mitochondria, but cannot induce apoptosis; the latter can be restored by ellipticine. 56 On the other hand, some p53 mutants preserve pro-apoptotic function, but lack the ability to translocate to mitochondria, which can be restored by Tid1.
57
TP53 point mutations in lymphoid malignancies occur most often in the p53 DBD (Figure 1 ), most frequently at codons 248, 273, and 175, similar to the codon distribution pattern in other types of cancer. 55 Four of the five mutations at these three codons, R175H, R248Q, R273H and R273C, occur in CpG sites which have elevated mutability (with the exception of R248W). The high frequency of these mutations is also a reflection of functional selection. 58 Codons 248 and 273 bind to minor and major grooves of DNA, and mutations at codon 175 disrupt p53 structure ( Figure 6D ). 59 Indeed, all five mutants have lost transactivation function in a p53-functional assay. 54 Codons 176, 158, 244, and 245 also have a high frequency of mutation.
Prognostic significance of p53 mutations in lymphoid malignancies
Despite the low frequency of p53 mutations in hematological malignancies, p53
mutations predict an unfavorable prognosis. 51, 60 The IARC prognosis dataset indicates that p53 mutations correlate with poor survival for patients with DLBCL, AML, myelodysplastic syndromes, ALL, CLL/SLL, FL, MCL, and MM. Our own studies have shown that TP53 mutations in the DBD significantly correlate with poorer OS in patients with DLBCL ( Figure   6 ). Concurrent p53 mutations and inactivation of other genes with prognostic impact (e.g., p21, p27, ATM, p16INK4a and ARF) have been correlated with a worse prognosis. As overexpression of p53 often correlates with p53 mutations, p53 immunohistochemical In a 138 B-CLL cohort, p53 mutations correlated with shorter OS and selective resistance to alkylating agents, fludarabine and γ -irradiation, but not to some other cytotoxic drugs functioning via p53-independent pathways. 61 Moreover, prior chemotherapy is strongly associated with the presence of p53 mutations. Exposure to DNA-damaging alkylating agents has been suggested as being responsible for the development of TP53 mutations and resistance to second-line anticancer chemotherapy. 61 In a more recent study, however, no clonal evolution of new TP53 mutants was identified following chemotherapy, immunotherapy, or bone marrow transplantation in 181 CLL patients.
62
In Lane's model of p53 function, tumor cells without functional p53 treated with low dose DNA-damaging agents survive and continue to replicate resulting in mutations and aneuploidy, whereas in cells treated with high dose DNA-damaging agents, replication attempts result in mitotic failure and cell death. 1 In contrast to the prevailing notion that WTp53 is associated with better prognosis, it has been suggested that in the absence of apoptosis, WT-p53 can protect tumor cells treated with ionizing radiation or chemotherapy from mitotic catastrophe or permanent arrest by mediating cell cycle arrest and DNA repair, and therefore serves as a survival factor. 37 WT-p53 also may serve as a survival factor for tumor cells when p53 induces autophagy that inhibits apoptosis. As reported by Amrein and colleagues, autophagy was induced only in primary CLL lymphocytes expressing WT-p53, and contributed to drug resistance.
16
Polymorphisms of p53 and association with lymphomagenesis TP53 has a number of polymorphisms, most of which occur in introns or UTRs, whereas 8 synonymous and 11 non-synonymous polymorphisms occur within the CDS. 63 The codon 72 polymorphism has been studied regarding its population prevalence and effects on p53 function. The p53 Pro72 variant has stronger transcriptional activity than Arg72, and is twice as stable as the Arg72 in Daudi (human BL) cells. Arg72 is also more susceptible to degradation induced by the human papillomavirus E6 protein. On the other hand, Arg72 has more capacity to induce apoptosis because of its greater ability to localize to mitochondria and lower affinity to the p53 inhibitor iASPP. 63 In one study, 4 of 25 (17.5%) ALL patients carried the R72P (Arg to Pro) polymorphism. 64 No association was found between this polymorphism and the risk or In PW lymphoma cells treated with L-buthionine sulfoximine/BSO, the full-length p53 level was unchanged, whereas a truncated isoform of p53 (about 50 kDa) was induced, reaching the highest level when apoptosis was induced irreversibly. 13 In contrast, the rapid shift from a truncated p53 (Δ, probably p53β) toward the full-length p53 expression was found responsible for the apoptosis and cytopenia as a response to chemotherapy in five AML patients. 86 These findings suggest that posttranscriptional dysregulation of TP53 may be implicated in lymphomagenesis. A single case of ALL with a one-nucleotide substitution in the 5′UTR of TP53 which might affect posttranscriptional regulation has been reported. 64 In addition to binding to p53 protein, MDM2 directly binds to the nucleotides of p53 mRNA corresponding to the MDM2-binding domain (MBD) of p53 and enhances TP53
translation. Cancer-derived silent-point-mutations in the MBD weaken MDM2 binding to p53 mRNA, leading to lower levels of p53 protein and apoptosis. 87 After p53 is translated, the E3 ligase activity of MDM2 leads to the rapid degradation of p53. 
Dysfunction of p53 Transcription-independent Activity (TIA)
The regulation of TIA of cytoplasmic p53 associated with apoptosis and autophagy is less elucidated than the regulation of TA of nuclear p53.
Tid1 (mtHsp40) and mono-ubiquitination of p53 promote translocation of p53 to mitochondria. 57,106 Acetylation of K120 is required for p53 to release BAK from Mcl-1, and for transcription-independent apoptosis. 3 Other posttranslational modifications and redox modulation also affect the translocation.
3,107
The E3 ubiquitin ligase, CUL-9/Parc, enhances the cytoplasmic function of p53 in vivo. CUL-9/Parc bound to p53 localized in the cytoplasm, and activated p53 cytoplasmic function in a mouse model, do not support former reports that CUL-9/Parc antagonized p53-mediated apoptosis by sequestering p53 in the cytoplasm. However, the specific biochemical mechanisms that activate p53 cytoplasmic function remain unclear. Deletion of Cul9
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Downstream dysregulation of the TP53 pathway
Lymphomagenesis can result from dysregulation of downstream p53-effectors by p53-independent pathways. In mucosal-associated lymphoid tissue (MALT) lymphomas, API2/MALT1, the result of the t(11;18)(q21;q21), activates nuclear factor-kappa B (NF-κB) signaling and inhibits p53-dependent apoptosis, although p53 is induced and subcellular localization is not changed. 117 Inhibitors of calpain protease or the proteasome also increased p53 stability and elevated p53 levels and apoptosis. 118 However, in MM, the proteasome inhibitor bortezomib significantly increased basal autophagy that was thought to protect myeloma cell viability. 44 Novel syrbactin analogs exhibiting proteasome inhibitory activity induced pro-apoptotic ER stress and cell death in MM and B-ALL cells, and might substitute for bortezomib. 119 Drugs targeting the dysregulated p53-dependent apoptosis pathway include Bcl-2 antisense oligonucleotides for CLL, XIAP inhibitor for CLL and ATLL, small-molecule inhibitors of Bcl-2/Bcl-X(L) for CLL, MCL, splenic marginal zone lymphoma, and Bcl-2-dependent lymphomas. 120 Stabilization and activation of p53 also can overcome downstream apoptosis pathway defects. MDM2 inhibitor Nutlin-3a increased intrinsic apoptosis in a preclinical model of DLBCL with WT-p53 and Bcl-2 overexpression due to t(14;18)(q32;q21). 121 Similarly, Nutlin-3a induced apoptotic death in ALK+ anaplastic large cell lymphoma (ALCL). 122 Interestingly, Nutlin-3a also enhanced doxorubicin cytotoxicity in p53-mut ALCL and DLBCL. This synergistic effect was suggested to be a result of p73 upregulation. 121, 122 The potential of anticancer drugs that function through p53-independent apoptosis pathways also has been explored. Hexavalent chromium Cr(VI) induced both p53-dependent and p53-independent apoptosis in U937 lymphoma cells without functional p53. 123 The Ca 2+ -calpain pathway and mitochondrial pathway played significant roles in Cr(VI)-induced G2 block and p53-independent apoptosis. ROS generation was involved in both pathways, while c-Jun-N-terminal kinase (JNK) and FAS activation were not detected. 123 The pro-apoptotic function of the Ca 2+ -calpain pathway in p53-deficient U937 cells is opposite to the inhibition of apoptosis by calcium mobilizer TG in M1-t-p53 cells, 110 and by calpain in LY-ar lymphoma cells with functional p53. 118 In fact, TG induced autophagy when used alone and increased apoptosis when combined with autophagy inhibitors in MM; 44 increased ER stress and apoptosis in human MM and B-ALL; 119 induced apoptosis in murine lymphoma cells; 124 and induced differential apoptosis in human T-cell lymphomas with or without PLCγ1 phospholipase. 125 Therefore, both apoptosis and autophagy can be induced by calcium flux, ROS, are affected by the proteasome or protease, and have effect on mitochondria. It will be interesting to investigate further whether and how apoptosis and autophagy induced by these drugs regulate each other in lymphomas and how their interaction varies according to p53
D. Therapeutic approaches to overcome p53 inactivation
status.
Similarly, Apoptin, DNA topoisomerase I inhibitor, gallium maltolate, Avicins, ionizing radiation combined with arsenic trioxide or staurosporine, cisplatin combined with rituximab or fludarabine, can induce p53-independent apoptosis pathways in lymphoma cells regardless of p53 status. 123, [126] [127] [128] [129] [130] [131] [132] [133] Nonapoptotic cell death mechanisms are also implicated in jasmonates (plant stress hormones)-induced cell death of murine B-lymphoma with severe ATP depletion, resulting from compromised oxidative phosphorylation in mitochondria. The authors suggested that apoptotic death in p53-wt cells is p53-independent, whereas nonapoptotic death, probably necrosis, is responsible for p53-mut cell death. 134 Non-canonical autophagy (Beclin1-independent) and apoptosis were simultaneously induced by a novel small-molecule compound C1 via ROS production and subsequent activation of extracellular signal-regulated kinase (ERK) and JNK in various cell lines. 135 More importantly, autophagy triggered by C1 is tumor cell specific, occurring in lymphoma cells but not reactive lymphocytes. 
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For Highly expressed in GC; loss leads to higher level of p53 in CLL * Seed match: The 2 nd to 7 th nucleotide of the miRNA 5′ region is known as the seed. There are four types of seed-matched sites on the 3′UTR of target mRNAs according to Bartel and colleagues: the 6mer site, which perfectly matches the 6-nt miRNA seed, the 7mer-m8 site, which comprises the seed match supplemented by a Watson-Crick match to miRNA nucleotide 8, the 7mer-A1 site, which comprises the seed match supplemented by an A across from miRNA nucleotide 1, and the 8mer site, which comprises the seed match supplemented by both the m8 and the A1. The hierarchy of site efficacy is as follows: 8mer > > 7mer-m8 > 7mer-A1 > > 6mer > no site, with the 6mer differing only slightly from no site at all. Interaction of miR-15/16:TP53 is unconventional. GC indicates germinal center; MM, multiple myeloma; CLL, chroninc lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; and FL, follicular lymphoma. Location of critical p53 residues in the p53 domain model designed from the published crystal structure. The mutations depicted are associated with poor outcome identified from our group study in 1187 DLBCL cases. The residues are color-coded as follows: green, mutation from or to proline; deep blue, light blue: residues close to either zinc or DNAbinding sites; brown: residues far from both zinc and DNA; orange: cysteine residues implicated in the oxidation-reduction activity of p53. and phosphorylation (e.g., by CK2, Chk2) inhibit ubiquitination, stabilize and enhance p53 activity, whereas neddylation (e.g., by FBXO11, NEDD) increases p53 stability but suppresses p53 function. However, association with p300 is required for MDM2-mediated polyubiquitination and degradation of p53. Methylation on different residues has different effects on p53. The methyltransferase SETD7 increases p53 stability; SETD8 inhibits p53 activity. Controversially, Setd7 is dispensable for the p53 function (cell-cycle arrest or apoptosis) in vivo. Effect of sumoylation is also controversial. Acetylation state of SUMO-1 affects its activity towards p53 stability. Ubiquitination decreases p53 stability and activity.
MDM2 mediates p53 degradation and inhibits p53 acetylation and activity. NUB1 decreases neddylation by NEDD8 and stimulates p53 ubiquitination, promotes cytoplasmic localization of p53 and inhibits p53 TA. The atypical ubiquitin ligase E4F1 has no effect on p53 
